Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Change in Account Payables (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Change in Account Payables for 7 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables rose 317.09% to $1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.0 million, a 234.26% increase, with the full-year FY2025 number at $6.0 million, up 234.26% from a year prior.
  • Change in Account Payables was $1.2 million for Q4 2025 at Beam Therapeutics, up from -$1.6 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $3.8 million in Q1 2025 to a low of -$3.0 million in Q3 2023.
  • A 5-year average of $173000.0 and a median of -$64500.0 in 2022 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: skyrocketed 1012.89% in 2021, then tumbled 2584.31% in 2023.
  • Beam Therapeutics' Change in Account Payables stood at $2.2 million in 2021, then skyrocketed by 34.32% to $2.9 million in 2022, then tumbled by 160.97% to -$1.8 million in 2023, then soared by 68.89% to -$550000.0 in 2024, then soared by 317.09% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Change in Account Payables are $1.2 million (Q4 2025), -$1.6 million (Q3 2025), and $2.6 million (Q2 2025).